News Takeda to cut IT, marketing and sales jobs after Shire merge... Takeda aiming for $1.4bn savings per year
News NICE asks EUSA pharma to drop price of neuroblastoma drug NICE calls for price cut before possible CDF funding
News Priority review voucher prices fall again after Spark's $110... Voucher prices have fallen since their 2015 peak
News Report warns of UK's rare disease 'postcode lottery' There is still a ‘postcode lottery’ for patients getting access to vital rare disease treatments in the UK, according to a new report.
News BMS' Opdivo shines as infectious disease franchise fades Bristol-Myers Squibb has been touted as a potential takeover target in the pharma industry – and potential buyers may take note of the continued strong performance of its cancer drug Opdivo
News Ultragenyx to slash costs after Angelman trial failure Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
